In the prospective arm of our study, we expanded our investigation to explore the expression of CD39 and CD73 within the extracellular vesicles (EVs) and their enzymatic activity in the blood samples both at the time of prostate cancer diagnosis and during the follow-up period. This evidence concerns the gene NT5E and prostate carcinoma.